YOLFTbeta
QU

Achieve Life Sciences, Inc.

QUIT · NASDAQ · Healthcare / Biotechnology

6.32USD

Price History

Full chart

Market Stats

Open6.30
Day Range5.93 – 6.43
52-Week Range2.62 – 8.64
Volume775.90K
Market Cap651.61M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.71
Dividend Yield0.00%
50-Day Avg6.66
200-Day Avg6.66

About

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Andrew D. Goldberg M.D.
  • Employees28
  • Headquarters22722 29th Dr. SE, Bothell, WA, United States, 98021, USA
  • Websitehttps://www.achievelifesciences.com

Leadership

  • Mr. Erik AtkissonChief Legal Officer · b. 1972
  • Dr. Andrew D. Goldberg M.D.CEO, President & Director · b. 1982
  • Mr. Benjamin Halladay M.B.A.Chief Financial Officer · b. 1986
  • Mr. Jerry WanVP of Finance & Principal Accounting Officer · b. 1982
  • Ms. Kaitlyn TusonSenior Vice President of Marketing & Communications
  • Dr. Mark L. Rubinstein M.D.Chief Medical Officer · b. 1968
  • Mr. Mark ZappiaSenior Vice President of Commercial
  • Mr. Ronald DadinoSenior Vice President of Chemistry, Manufacturing & Controls and Supply Chain
  • Ms. Gloria CosgroveSenior Vice President of Global Quality
  • Ms. Nicole P. JonesVice President of Strategic Communications & Stakeholder Relations

Financials

Income Statement

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Revenue0000
Cost of Revenue--229.00K228.00K
Gross Profit---229.00K-228.00K
Operating Expense--38.84M54.65M
Operating Income-40.80M-27.25M-39.07M-54.88M
EBITDA-40.33M-26.73M-37.42M-53.60M
Net Income-42.35M-29.82M-39.83M-54.65M
R&D30.08M15.81M22.82M22.96M
Interest Expense1.79M2.85M2.18M819.00K

Balance Sheet

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Assets29.97M19.37M38.63M41.79M
Total Liabilities21.67M20.82M17.73M20.27M
Total Equity8.30M-1.45M20.90M21.52M
Cash24.72M15.55M12.73M20.93M
Total Debt16.20M16.73M9.96M14.96M
Net Debt-8.52M1.19M-2.77M-5.97M

Cash Flow

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-37.57M-24.48M-29.77M-49.47M
Investing Cash Flow--21.00K-21.58M6.11M
Financing Cash Flow19.32M15.28M48.53M51.53M
Capital Expenditure021.00K03.00K
Free Cash Flow-37.57M-24.50M-29.77M-49.47M
FCF to OCF100.00%100.09%100.00%100.01%

Earnings

Report DateMar 31, 1998Jun 30, 1998Sep 30, 1998Mar 31, 1999Jun 30, 1999Sep 30, 1999Mar 31, 2000Jun 30, 2000Sep 30, 2000Mar 31, 2001Jun 30, 2001Sep 30, 2001Dec 31, 2001Mar 31, 2002Jun 30, 2002Sep 30, 2002Dec 31, 2002Mar 31, 2003Jul 11, 2003Nov 6, 2003Feb 11, 2004Apr 22, 2004Jul 21, 2004Nov 3, 2004Mar 23, 2005May 9, 2005Aug 8, 2005Nov 8, 2005Mar 16, 2006May 10, 2006Aug 9, 2006Nov 8, 2006Mar 15, 2007May 10, 2007Aug 3, 2007Nov 12, 2007Mar 6, 2008May 9, 2008Aug 5, 2008Nov 10, 2008Mar 11, 2009May 7, 2009Aug 7, 2009Nov 6, 2009Mar 9, 2010May 7, 2010Aug 6, 2010Nov 5, 2010Mar 11, 2011May 10, 2011Aug 5, 2011Nov 4, 2011Mar 9, 2012May 4, 2012Aug 3, 2012Nov 9, 2012Mar 8, 2013May 3, 2013Aug 9, 2013Nov 8, 2013Mar 12, 2014May 1, 2014Aug 8, 2014Oct 31, 2014Mar 27, 2015May 15, 2015Aug 14, 2015Nov 13, 2015Mar 10, 2016May 13, 2016Aug 5, 2016Nov 11, 2016Feb 23, 2017May 15, 2017Aug 3, 2017Nov 10, 2017Mar 8, 2018May 10, 2018Aug 9, 2018Nov 8, 2018Mar 15, 2019May 16, 2019Aug 9, 2019Nov 6, 2019Mar 13, 2020May 14, 2020Aug 6, 2020Nov 13, 2020Mar 12, 2021May 13, 2021Aug 12, 2021Nov 10, 2021Mar 10, 2022May 13, 2022Aug 12, 2022Nov 15, 2022Mar 17, 2023May 10, 2023Aug 15, 2023Nov 10, 2023Mar 29, 2024May 10, 2024Aug 14, 2024Nov 8, 2024Mar 11, 2025May 13, 2025Aug 7, 2025Nov 6, 2025Mar 24, 2026May 12, 2026Aug 11, 2026Nov 19, 2026
EPS Estimate-------------------------------------------------------------------------------------------------------------0.28-0.30-0.16-0.20
EPS Actual-15019.41-14235.72-9404.60-6335.56-14146.528331.25-9386.028862.44-9367.46-3175.60-7260.9617771.13-7524.00-7206.10-10280.77-9478.02-7128.00-6575.47-8894.08-5941.91-5761.69-7852.36-7458.72-6712.11-10520.41-8855.69-7578.09-14801.31-4305.51-6867.42-5633.24-6772.79-7996.14-3465.67-6402.28-6228.292070.23-4398.18-4067.564449.47-8712.00-955.58-1808.58-888.411409.53-1057.4051.89-2350.00-691.03-689.66-1478.25979.11-2163.74-1474.51-637.12-890.84-616.00-1004.96-1262.39-1505.60-998.91-1290.58-1029.71-512.13-581.43-438.62-563.00-350.75-127.26-273.42-506.33-270.47-428.18-239.12-219.58-179.14-63.40-48.62-36.46-14.29-10.92-17.57-10.08-9.07-5.91-2.15-1.68-1.14-1.11-1.30-1.53-0.71-0.76-0.80-1.08-1.35-0.83-0.50-0.43-0.34-0.26-0.26-0.25-0.36-0.36-0.37-0.37-0.28-0.28-0.19-0.80-0.11
Surprise-------------------------------------------------------------------------------------------------------------1.19%36.37%-400.00%44.75%
Timing----------------------------------------------------------------------------------------------------------------

Key Statistics & Ratios

Market Cap651.61M
Enterprise Value503.55M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.82
EPS-1.71
Book Value1.65
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-63.89M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-104.23%
Return on Assets-31.01%
Shares Outstanding103.10M
Shares Float79.87M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 11 analystsTarget 14.58
  • Strong Buy
    8
  • Buy
    3